

# Joel W Hay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4534610/publications.pdf>

Version: 2024-02-01

136  
papers

5,004  
citations

117571

34  
h-index

98753

67  
g-index

141  
all docs

141  
docs citations

141  
times ranked

6095  
citing authors

#	ARTICLE	IF	CITATIONS
1	Flexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis. BMC Urology, 2022, 22, 76.	0.6	0
2	Reconstruction After Salvage Total Laryngectomy: A Cost-Effectiveness Analysis. Otolaryngology - Head and Neck Surgery, 2021, 164, 139-145.	1.1	5
3	The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding. JAMA Internal Medicine, 2021, 181, 137.	2.6	0
4	A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. Journal of General Internal Medicine, 2021, 36, 1292-1301.	1.3	51
5	Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clinical Microbiology and Infection, 2021, 27, 1448-1454.	2.8	14
6	Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care. Genetics in Medicine, 2021, 23, 1854-1863.	1.1	4
7	Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases. Value in Health, 2021, 24, 917-924.	0.1	5
8	Neonates with mild hypoxic-ischaemic encephalopathy receiving supportive care versus therapeutic hypothermia in California. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, , fetalneonatal-2021-322250.	1.4	7
9	Quality of Life in the Swedish General Population During COVID-19 - Based on pre- and post-pandemic outbreak measurement. Nordic Journal of Health Economics, 2021, 9, 56-73.	0.2	7
10	There is Insufficient Evidence to Support a Causal Relationship Between Chili Pepper Consumption and Mortality. Journal of the American College of Cardiology, 2020, 75, 1864.	1.2	5
11	Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 428-434.	0.6	6
12	Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection. Journal of General Internal Medicine, 2020, 35, 1102-1110.	1.3	6
13	Hypertension and Unlikely Causality in the Association Between Soft Drink Consumption and Mortality. JAMA Internal Medicine, 2020, 180, 335.	2.6	1
14	Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". International Journal of Health Policy and Management, 2020, 9, 352-355.	0.5	1
15	A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. Journal of Asthma, 2019, 56, 872-881.	0.9	15
16	Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. Journal of General Internal Medicine, 2019, 34, 846-854.	1.3	20
17	Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis. Journal of Perinatology, 2019, 39, 571-580.	0.9	15
18	Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling. Value in Health, 2019, 22, 564-569.	0.1	8

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. <i>Annals of Pharmacotherapy</i> , 2019, 53, 134-143.	0.9	24
20	Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. <i>International Journal of Cardiology</i> , 2019, 282, 53-58.	0.8	14
21	Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-to-Severe Crohn's Disease in Biologic-Naïve Patients. <i>Pharmacotherapy</i> , 2019, 39, 118-128.	1.2	9
22	Lifestyle intervention for adults with spinal cord injury: Results of the USC's RLANRC Pressure Ulcer Prevention Study. <i>Journal of Spinal Cord Medicine</i> , 2019, 42, 2-19.	0.7	25
23	Cost-Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes. <i>Value in Health</i> , 2018, 21, 561-568.	0.1	25
24	Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. <i>Health Services and Outcomes Research Methodology</i> , 2018, 18, 75-95.	0.8	0
25	Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 30.	0.6	2
26	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2018, 17, e751-e761.	1.0	37
27	First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. <i>Lung Cancer</i> , 2018, 123, 166-171.	0.9	31
28	Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e147.	2.1	26
29	A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIIa On-Demand. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 149-157.	0.5	8
30	A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2016, 63, 1495-1504.	2.9	53
31	Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment. <i>BMJ Open</i> , 2016, 6, e012739.	0.8	13
32	Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 562.	3.8	663
33	Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 641-647.	0.5	4
34	Understanding patient preferences and willingness to pay for hemophilia therapies. <i>Patient Preference and Adherence</i> , 2015, 9, 1623.	0.8	24
35	Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. <i>International Journal of Cardiology</i> , 2015, 181, 417-424.	0.8	32
36	Marijuana Use in Models for Health Outcomes. <i>American Journal of Medicine</i> , 2015, 128, e23.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey. <i>Annals of Epidemiology</i> , 2015, 25, 486-491.	0.9	22
38	Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 267-283.	0.7	13
39	Promise of Precision Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1752.	3.8	2
40	A Special Commemorative Issue Honoring William S. Comanor and 50 Years of Pharmaceutical Economics. <i>International Journal of the Economics of Business</i> , 2015, 22, 165-168.	1.0	0
41	Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon- $\beta$ 1a in Relapsing-Remitting Multiple Sclerosis. <i>CNS Drugs</i> , 2015, 29, 71-81.	2.7	22
42	Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 545-558.	0.7	0
43	Implementing trials of complex interventions in community settings: The USCâ€“Rancho Los Amigos Pressure Ulcer Prevention Study (PUPS). <i>Clinical Trials</i> , 2014, 11, 218-229.	0.7	19
44	Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 677-683.	0.6	32
45	A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments. <i>Pharmacoeconomics</i> , 2014, 32, 1201-1212.	1.7	49
46	Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1417-1425.	2.3	27
47	Current Issues in Pharmacoeconomic Modeling. <i>The Journal of Health Technology Assessment</i> , 2014, 2, 6-9.	0.2	0
48	INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. <i>Health Economics (United Kingdom)</i> , 2013, 22, 807-823.	0.8	4
49	Costâ€“benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). <i>Vaccine</i> , 2013, 31, 2558-2564.	1.7	7
50	Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. <i>BMC Pediatrics</i> , 2013, 13, 127.	0.7	71
51	Depression treatment preferences of older white and Mexican origin men. <i>General Hospital Psychiatry</i> , 2013, 35, 59-65.	1.2	26
52	Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. <i>Pharmacoeconomics</i> , 2013, 31, 823-839.	1.7	27
53	Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. <i>Journal of Medical Economics</i> , 2013, 16, 1082-1088.	1.0	6
54	The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. <i>Neuro-Oncology</i> , 2013, 15, 1532-1542.	0.6	29

#	ARTICLE	IF	CITATIONS
55	Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. <i>Haemophilia</i> , 2013, 19, 711-719.	1.0	3
56	Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia. <i>PLoS ONE</i> , 2013, 8, e80639.	1.1	17
57	Costs of Necrotizing Enterocolitis and Cost-Effectiveness of Exclusively Human Milk-Based Products in Feeding Extremely Premature Infants. <i>Breastfeeding Medicine</i> , 2012, 7, 29-37.	0.8	176
58	Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. <i>Journal of Epidemiology and Community Health</i> , 2012, 66, 782-790.	2.0	327
59	Cost-Benefit Analysis of In-Hospital Influenza Vaccination of Postpartum Women. <i>Obstetrics and Gynecology</i> , 2012, 119, 306-314.	1.2	13
60	Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes. <i>Value in Health</i> , 2012, 15, 249-254.	0.1	58
61	Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity score and instrumental variable methods to adjust for treatment selection bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 470-484.	0.9	19
62	Efficacy of Bypassing Agents in Patients With Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2012, 34, 434-445.	1.1	11
63	Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 211-221.	0.6	88
64	Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2011, 17, e969-74.	1.0	16
65	Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. <i>Journal of Medical Economics</i> , 2011, 14, 516-525.	1.0	9
66	Effectiveness of Collaborative Care in Addressing Depression Treatment Preferences Among Low-Income Latinos. <i>Psychiatric Services</i> , 2010, 61, 1112-1118.	1.1	52
67	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report Part IV. <i>Value in Health</i> , 2010, 13, 18-24.	0.1	22
68	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report Part II. <i>Value in Health</i> , 2010, 13, 8-13.	0.1	120
69	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report Part III. <i>Value in Health</i> , 2010, 13, 14-17.	0.1	21
70	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report Part VI. <i>Value in Health</i> , 2010, 13, 28-33.	0.1	80
71	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report Part I. <i>Value in Health</i> , 2010, 13, 3-7.	0.1	81
72	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report Part V. <i>Value in Health</i> , 2010, 13, 25-27.	0.1	10

#	ARTICLE	IF	CITATIONS
73	Commentary on Knight <i>et al.</i> : A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. <i>Haemophilia</i> , 2010, 16, 366-368.	1.0	5
74	Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. <i>General Dentistry</i> , 2010, 58, 484-92; quiz 493-4.	0.4	9
75	Cost-effectiveness analysis of lapatinib in HER2-positive advanced breast cancer. <i>Cancer</i> , 2009, 115, 489-498.	2.0	48
76	Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease. <i>Value in Health</i> , 2009, 12, 262-266.	0.1	18
77	Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. <i>Current Medical Research and Opinion</i> , 2009, 25, 1421-1431.	0.9	7
78	Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 634-642.	1.0	13
79	Asthma costs and utilization in a managed care organization. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 885-892.e5.	1.5	35
80	Using Pharmacoeconomics to Value Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 197-200.	2.3	11
81	A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. <i>International Journal of Angiology</i> , 2008, 17, 78-82.	0.2	1
82	The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. <i>American Heart Journal</i> , 2007, 154, 267-277.	1.2	63
83	A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2775-2787.	0.9	21
84	Prices, regulation and innovation in pharmaceuticals and biotechnology. <i>Research in Human Capital and Development</i> , 2007, , 81-99.	0.1	1
85	Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2006, 24, 1221-1232.	1.7	47
86	Comparing Patient Access to Pharmaceuticals in the??UK and US. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 269-270.	1.0	1
87	Where's the Value in Health Care?. <i>Value in Health</i> , 2006, 9, 141-143.	0.1	14
88	Economic Considerations for Pertussis Booster Vaccination in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, S127-S133.	1.1	28
89	Cost and Utilization Impacts of Oral Antihistamines in the California Medi-Cal Program. <i>Value in Health</i> , 2005, 8, 506-516.	0.1	8
90	The cost effectiveness of cardiovascular medicines. <i>Current Atherosclerosis Reports</i> , 2005, 7, 79-80.	2.0	4

#	ARTICLE	IF	CITATIONS
91	The Application of Cost-Effectiveness and Cost-Benefit Analysis to Pharmaceuticals. , 2005, , 225-248.		1
92	Appropriate Econometric Methods for Pharmacoeconomic Studies of Retrospective Claims Data: An Introductory Guide. Journal of Managed Care Pharmacy, 2005, 11, 344-348.	2.2	11
93	Implementation and Outcomes of Commercial Disease Management Programs in the United States: The Disease Management Outcomes Consolidation Survey. Disease Management: DM, 2005, 8, 253-264.	1.0	15
94	Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease. Pharmacoeconomics, 2005, 23, 133-141.	1.7	28
95	Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot?? in the Acute Treatment of Migraine. CNS Drugs, 2005, 19, 635-642.	2.7	13
96	Medicare Coverage and Reimbursement of Outpatient Prescription Drugs in the US. Applied Health Economics and Health Policy, 2005, 4, 9-14.	1.0	1
97	Using Conjoint Analysis to Assess Depression Treatment Preferences Among Low-Income Latinos. Psychiatric Services, 2004, 55, 934-936.	1.1	71
98	Evaluation of Strategies for Use of Acellular Pertussis Vaccine in Adolescents and Adults: A Cost-Benefit Analysis. Clinical Infectious Diseases, 2004, 39, 20-28.	2.9	107
99	Cost-Effectiveness of Primary Implanted Cardioverter Defibrillator for Sudden Death Prevention in Congestive Heart Failure. Cardiovascular Drugs and Therapy, 2004, 18, 161-170.	1.3	38
100	Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 625-634.	0.7	13
101	Evaluation and review of pharmacoeconomic models. Expert Opinion on Pharmacotherapy, 2004, 5, 1867-1880.	0.9	27
102	Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program. Value in Health, 2003, 6, 425-435.	0.1	35
103	Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003, 41, 32-44.	1.1	253
104	Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES. Journal of Managed Care Pharmacy, 2003, 9, 53-61.	2.2	260
105	Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. American Journal of Managed Care, 2003, 9, 45-56.	0.8	24
106	Hospital cost drivers: an evaluation of 1998-2001 state-level data. American Journal of Managed Care, 2003, 9 Spec No 1, SP13-24.	0.8	11
107	Cost-Effectiveness of Preventive Occupational Therapy for Independent-Living Older Adults. Journal of the American Geriatrics Society, 2002, 50, 1381-1388.	1.3	106
108	Pharmacoeconomic Guidelines: Where Do We Go from Here?. Value in Health, 2001, 4, 211.	0.1	3

#	ARTICLE	IF	CITATIONS
109	Commentary: Pharmacoeconomics and Outcomes Research: Expanding the Healthcare "Outcomes" Market. Value in Health, 2000, 3, 181-185.	0.1	1
110	An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. , 2000, 17, 911-919.		3
111	Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary. Value in Health, 1999, 2, 67-72.	0.1	3
112	Panel 2: Methodological Issues in Conducting Pharmacoeconomic Evaluations" Modeling Studies. Value in Health, 1999, 2, 78-81.	0.1	28
113	Health Care Costs and Outcomes: How Should We Evaluate Real World Data?. Value in Health, 1999, 2, 417-419.	0.1	11
114	Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease. Pharmacoeconomics, 1999, 15, 47-74.	1.7	77
115	Introduction to the ISPOR Lipid Conference. Value in Health, 1998, 1, 95-99.	0.1	1
116	A Direction for Value in Health. Value in Health, 1998, 1, 149-154.	0.1	1
117	The ISPOR Lipid Conference: Pharmacoeconomics and Outcomes Modeling Issues. Value in Health, 1998, 1, 155-158.	0.1	0
118	Economic Modeling and Sensitivity Analysis. Value in Health, 1998, 1, 187-193.	0.1	14
119	From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum. Value in Health, 1998, 1, 243-250.	0.1	0
120	The Kaiser Permanente/USC Patient Consultation Study: Change in use and cost of health care services. American Journal of Health-System Pharmacy, 1998, 55, 2485-2499.	0.5	31
121	Cost of lipid-lowering statin drugs. American Journal of Cardiology, 1996, 77, 225-226.	0.7	3
122	Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.. American Journal of Cardiology, 1996, 78, 409-414.	0.7	99
123	Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser permanente/USC patient consultation study. Clinical Therapeutics, 1995, 17, 1188-1206.	1.1	19
124	Comment: Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist. Annals of Pharmacotherapy, 1994, 28, 539-539.	0.9	1
125	Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 309-317.	1.1	222
126	Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 318-327.	1.1	107



#	ARTICLE	IF	CITATIONS
127	An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. <i>American Journal of Cardiology</i> , 1991, 67, 789-796.	0.7	69
128	Cost-benefit analysis of Haemophilus influenzae type b prevention. <i>Pediatric Infectious Disease Journal</i> , 1990, 9, 246-251.	1.1	38
129	Medical costs of coronary artery disease in the United States. <i>American Journal of Cardiology</i> , 1990, 65, 432-440.	0.7	93
130	Econometric issues in modeling the costs of AIDS. <i>Health Policy</i> , 1989, 11, 125-145.	1.4	14
131	Ordinary Least Squares and Sample-Selection Models of Health-Care Demand: Monte Carlo Comparison. <i>Journal of Business and Economic Statistics</i> , 1987, 5, 499.	1.8	20
132	Medicare Pricing Mechanisms for Physician Services: An Overview of Alternative Approaches. <i>Medical Care Review</i> , 1986, 43, 59-100.	0.9	1
133	Let Them Eat Cake: A Note on Comparing Alternative Models of the Demand for Medical Care. <i>Journal of Business and Economic Statistics</i> , 1984, 2, 279.	1.8	46
134	The Impact of Public Health Care Financing Policies on Private-Sector Hospital Costs. <i>Journal of Health Politics, Policy and Law</i> , 1983, 7, 945-952.	0.9	24
135	Physician-induced demand. <i>Journal of Health Economics</i> , 1982, 1, 231-244.	1.3	57
136	Effects of fluoride and regular dental care on personal dental expenditures of young adults in Finland. <i>Community Dentistry and Oral Epidemiology</i> , 1982, 10, 15-22.	0.9	3